DEL BOIL-EASE BENZOCAINE STUDY ON SEVEN-DAY USE REQUESTED BY FDA
This article was originally published in The Tan Sheet
Executive Summary
DEL BOIL-EASE BENZOCAINE STUDY ON SEVEN-DAY USE REQUESTED BY FDA at an April 21 "OTC feedback" meeting on the inclusion of benzocaine for the relief of pain associated with boils in the external analgesics monograph, The agency indicated that it would accept Del Pharmaceuticals' petition to allow a 20% benzocaine ointment under the external analgesic monograph with a pain relief indication for boils, However, FDAers questioned the company's proposed dosing of "three-to-four times daily" and seven-day duration of use, given the scope of the data that were submitted to FDA by Del.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning